Komori
CellSource (4880) · InitiativeAdvanced

Incentives to Improve Business Performance through Stock Acquisition Rights for Employees and External Collaborators

First written in FY2020-Q2. 6 of 8 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2025-H1.

8entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020-Q2 – FY2020AdvancedFY2021-Q1 – FY2025-H12020: 120202021: 220212022: 120222023: 220232024: 120242025: 12025
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 656 companies write about · 0 as a headwind · 737 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 739 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 12 June 2025, we resolved to issue stock acquisition rights as stock options pursuant to Articles 236, 238 and 240 of the Companies Act.」

    It was decided to issue 1,582 stock acquisition rights, equivalent to 158,200 common shares, to 2 employees. The exercise period is from 13 June 2027 to 12 June 2035.
  2. FY2024-Q1AdvancedAnnual report

    「We will issue stock acquisition rights free of charge to our external collaborators for the purpose of further enhancing their motivation and morale to improve our performance.」

    On 12 March 2024, after the end of the fiscal year, it was decided to issue 80 stock acquisition rights, equivalent to 8,000 common shares, to 1 external collaborator. The exercise period is from 13 March 2026 to 24 January 2034.
  3. FY2023-Q1AdvancedAnnual report

    「The stock acquisition rights issued during the cumulative first quarter are as follows. (10th Series of Stock Acquisition Rights) Date of resolution: 30 November 2022 Categories and number of eligible persons (people): Employees of the company 29 Number of stock acquisition rights (units): 42 Class, details and number of shares underlying the stock acquisition rights (shares): Common shares 4,200」

    Specific implementation was added to grant 42 10th-series stock acquisition rights, equivalent to 4,200 common shares, to 29 employees.
  4. FY2022AdvancedAnnual report

    「10th Series of Stock Acquisition Rights: Categories and number of eligible persons (people): Employees of the company 29」

    The grant of 42 10th-series stock acquisition rights, equivalent to 4,200 common shares, to 29 employees was newly disclosed.
  5. FY2021AdvancedAnnual report

    「9th Series of Stock Acquisition Rights: Categories and number of eligible persons (people): Employees of the company 38」

    As the 9th series of stock acquisition rights approved on 4 October 2021, a specific plan was added to grant 38 employees rights equivalent to 5,400 common shares.
  6. FY2021-Q1AdvancedAnnual report

    「The stock acquisition rights issued during the first quarter of the current fiscal year are as follows.」

    As the 7th series of stock acquisition rights, rights equivalent to 2,000 common shares were granted to 2 external collaborators; as the 8th series, rights equivalent to 3,000 common shares were granted to 3 employees. The specific implementation of incentives to increase corporate value for employees and external collaborators progressed.
  7. FY2020RestatedAnnual report

    「We grant stock acquisition rights to our directors, employees and external collaborators pursuant to Articles 236, 238 and 239 of the Companies Act, for the purposes of providing incentives to increase long-term corporate value and securing talented personnel.」

    The policy of granting stock acquisition rights to employees, external collaborators and others as an incentive to increase corporate value and a means of securing talent continues.
  8. FY2020-Q2First statedAnnual report

    「We will issue stock acquisition rights free of charge to our employees and external collaborators for the purpose of further enhancing their motivation and morale to improve our performance. Date of issue of stock acquisition rights: 10 June 2020; number of stock acquisition rights issued: 34 (100 common shares per stock acquisition right); exercise period: 10 June 2022 to 28 January 2030」

    Specific measures were presented to issue stock acquisition rights to 13 employees and 5 external collaborators as a means of enhancing their motivation and morale to improve performance.
Moved together

"Increase in Partner Medical Institutions and Expansion into New Treatment Areas" moved the same way as this thread, in the same document, in 6 of its 8 moves.

644322★123456
  1. ★This thread
  2. 1Increase in Partner Medical Institutions and Expansion into New Treatment Areas6×
  3. 2Improving contract processing capacity4×
  4. 3Revenue and Profit Growth Since Founding and Expansion of the Regenerative Medicine-Related Business4×
  5. 4Decline in Patient Visits and Contract Processing Volumes Due to COVID-193×
  6. 5Joint Research on Exosomes and Their Clinical Application and Commercialisation2×
  7. 6Expansion of the Direct-Sales Model and Growth in the OEM Product Lineup2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for CellSource yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.